IMGN - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the ImmunoGen Fourth Quarter 2018 and Year-End Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the call over to Ms. Courtney O’Konek. Please go ahead.

Courtney O’Konek

you today's thank and morning for call. joining Good press includes and a today, results. quarter we of that a issued operating XXXX progress Earlier summary release our full year and fourth recent a press Investors the section recording This Media and of call found and at can website our this of under be immunogen.com. release

Business our Foster, Officer; today Rich Gregory, Officer, Chief are call President Blaine the will team Medical our Enyedy, our join Dave and for session. Chief Chief Scientific Officer CEO, Accounting Officer On the Mark and our Mckee, Chief Anna and Berkenblit; the our Q&A

During key review business our the we milestones. results today's months, and over quarter upcoming call, financial year-end will recent accomplishments fourth XX and highlight the last discuss with

and from uncertainties are differ turn results During the over And our in an SEC discussion, actual filings. to such Mark. risks that, and Descriptions with we materially of associated the with in our ImmunoGen investment I'll statements, may included will call statements. forward-looking the use

Mark Enyedy

Thank was another everyone, you, X, XXXX progress rapid in and execution the our the of us for of the for enrollment a and in registration Mirvetuximab ovarian for of our earlier-stage label platinum-resistant of over significant advancement study data combination joining this and completion XXX cancer, Courtney. support for FORWARD to thank led year today. by you and Good patients presentation ImmunoGen, expansion program morning, portfolio.

submission deliver program in XXXX targeting year; with our before additional from topline to the of year, and AML the studies the entered With year. and malignancies, next half IND results in we monotherapy I the finally the end on data half in number programs BLA and and the development FORWARD expansion first our of Mirvetuximab for BPDCN of potential Mirvetuximab combination IMGCXXX in from studies for benefit hematological this the of catalyst MAA from poised a second important including performance, for of

deliver balance strong on of management and and year deep generate This strategy coming also value the Oncology that with brings in We sheet the execute a experience capabilities well team to proven combination and the year. in to our completed on commercialization business. a us and positions significant (inaudible) development

we’ve and set complete Mirvetuximab for the the in As for of company; platinum-resistant a first, strategic the four ovarian priorities launch reminder, treatment women with development cancer. XXXX

malignancies; innovation accelerate maintain hematological that next, our the financial partnerships. build expand through value on of position platform Second, in leadership IGN programs innovation; and and strength high our up continued ADCs finally, in reach through

last objectives. towards months each significant the these we’ve progress XX Over of made

the pre-specified well patient For successfully for of in staged goal a Mirvetuximab, and the for reflects preliminary oncology and a pre-commercial disease. for study a which assessment June, for Mirvetuximab and the the and ovarian cancer diagnostic market our we commercial approach designation we’ve we the Mirvetuximab. our validated completed and a communities’ to opportunity for We FORWARD alpha ability out thorough I receptor program, and new ahead interim inventory, completed is in treatment team. commercial drug In need folate PMA date, companion the in granted believe now interest this product launch a track the advanced activities this of as the for fast with April, in rapid for began the To readiness finished and model. accrual building Mirvetuximab submission We futility initiated go-to-market underscores FDA schedule. analysis progressed enrollment and year

ovarian cancer and we for of single Mirvetuximab, submit are for to the we of platinum-resistant on an execution, the data therapy as a the of year. to would with full FORWARD in treatment MAA this track of in report strength X second BLA the topline year, from of the data agent first the On half women positive half approval with expect

In addition Mirvetuximab treatment expand of to FORWARD our the to setting study earlier to advance the we benefit to in II continue for indication, monotherapy ovarian cancer.

patients Over Mirvetuximab data doublets of from Keytruda, FORWARD in our XXX the ovarian more XXXX, and cancer. on Avastin with combination II course or than study of a with we women and presented Carboplatin platinum-sensitive platinum-resistant

XXX also combination which encouraging enrollment patient has Mirvetuximab, completed hematological in malignancies results in novel We evaluating Mirvetuximab carboplatin IGN demonstrated were (inaudible) at triple our ASH and early the plus cohort in Avastin. December. XXX program presented and

also XXX significant has platform, the of which developed the potential IMGCXXX, additional year. candidate pipeline first-in-class create stage ImmunoGen. the these end of development early to value the each IND to promising in Together file a being for ADAMX-targeting next We before with plan yielded the ADC our assets Our collaboration for our MacroGenics. with has

XXXX also and We $XXX of last number operational release for balance started a approximately Kadcyla details. oversubscribed of $XXX royalties milestones on sale this to year With net remainder a recently the in press including June, million. most the upsize these and raised covered sheet. the proceeds rights Through secondary of of with our an achieved residual to transactions, sales financial results, respect mornings’ commercial on receive over $XX our in we that our million the

the and in So over $XXX Mirvetuximab million XXX cost driven and of a trial R&D expenses clinical pre-commercial which activities million Mirvetuximab manufacturing. generated XXX was revenue expenses full million by course XX year briefly were mostly notably the we year, of from the in for operating approximately

a from pipeline will XXX year expenses XXX us With mentioned cash be fund that, to XXX of collaborators million progress. cash I to that release I’ll first XXXX and XX, topline half anticipate at least cash the over between Anna? cash X Anna XXX to and current be our expected XXX a For review We and guidance, beyond XXXX between operating as in with our XXXX. we between million combined XX receipts XX partners at the December and million. million operations enable which from revenues trial, and is phase results expected financial to and to million, turn our equivalents expect the million of the call

Anna Berkenblit

Thanks Mark.

as XXXX bring XXXX. to Mirvetuximab mentioned our was to of which women significant in objective, is progress platinum-resistant priority market monotherapy cancer As with another for ovarian year towards highest

in the studies expressions, subset folate patients to the a encouraging or we alpha and FORWARD cancer folate in believe phase in platinum-resistant The Mirvetuximab central to blinded months end or safety is year. X receive doxorubicin, well has the activity study resistant randomized to with plans study chemotherapy setting, meeting clinical two at look study later well; have to folate three positive designed primary on expressions. review as by free a one Mirvetuximab medium as assessing the the with to as who platinum ovarian coming includes independent single pivotal in PFS paclitaxel population we Liposomal Based receptor trial a treatment the data or with and consistent high the receptor choice regimen. is weekly high of physicians this medical was receptor the of point alpha XXX survival observed and both progression that date, forward entire enroll topotecan. which Our topline The potential received I the in progressing agent treatment patients up prior alpha to to to present patients and displace data

alpha the Mirvetuximab ovarian at in Avastin Mirvetuximab patients that as monotherapy, platinum-resistant receptor or with triple Mirvetuximab platinum in sensitive and carboplatin recurrent disease. in to a looking well in cohorts advancing Keytruda expansion trial, we Avastin is addition combination folate with positive the as combination are II evaluating with In cohort cancer, combination patients FORWARD plus

Mirvetuximab XXXX, of course the over Avastin reported ovarian earlier, combination in XXX or a than mentioned treated Mark with on patients, Keytruda. we’ve As either more with data cancer

of established And with no anti-tumor we carboplatin doses can activity have triplet We cohort ahead safety signals. the combination patients XX the quarter, in completed that we In combined of be schedule. full Keytruda the reported full encouraging Avastin, have and across new doublet dose first of Mirvetuximab cohort. with safely initial enrollment

of doublet that candidate as plus the In not calling Avastin. meet addition, of to is a may nevertheless a Avastin, within combination initiated containing the reported or Mirvetuximab we’re are encouraging based plus a they population on but such recurring we may appropriate of that who in cohort Mirvetuximab platinum platinum, with Avastin months agnostic. patient second with six in criteria These are date patients for Mirvetuximab data non-platinum (inaudible) platinum-resistance

to enroll doublet. combination to this XX XX for generate expansion label We guide patients approximately expect to to additional data

end, continues, of FORWARD and to as at cancer meetings As our II triplet establish the support to to earlier from over this the cohort plan initial combination course lines goal well present Mirvetuximab in expansion we XXXX. in medical choice cancer data cohort as the doublet To as mature remains agent therapy. use ovarian of ovarian data its of

with a these several Last both for approval on in a programs programs, from granted XXX BPDCM. IGN of Moving orphan recent are investigated FDA IMGN the and being treatment need in AML patients. malignancies XXX IMGN these new to and designation hematological for AML. were of remains the novel drug significant Despite AML treatment for years, year, our focus

designed payload, of class. the limitations DNA are acting are cross-linking IGN to this agents first-generation overcome new agents Our of which

Our XXX study Encouragingly X AML believe and strand of repeat in dosing year for payload. across patients. we XXX XXX in all the IGN XXX in while payload in Enrollment the most and on which retaining potent CDXXX of expect of anti-leukemia development patients will identify we the programs as can year. refractory with targeting we our DNA displayed in anti-leukemia IMGN forward our or ADC, again IMGN additional AML. schedule schedule sparing across activity BPDCM to BPDCM cohorts this with deploys move is XXX level presented recommended with find AML. which dosing reported facilitate at up phase to doses oral phase the IMGN to ongoing mg/ of in XXX displays just X phase IGN ASH, ASH that in in we us X activity establish potent combination one from we safety to encouraging XX% targeting doses testing a and provide regimen which saw This healthy and tolerable data move data combination IMGN December CDXX expansion in kg. of Initial treatment. than that relapsed repeat profile AML with doses presentation. monotherapy at we X.X ADC tolerability range showed relapse that a In in IMGN favorable to phase refractory back-to-back studies initiate both is relapsed IGN dosing as data forward plan (inaudible) cells X normal quite anti-tumor activity recommended more is to dose so well

ahead, coming notably clinical FORWARD data I XXXX months. we look in the we topline milestones have with the most important As in

over call Mark. to the back turn I’ll Now

Mark Enyedy

from a back momentum business of forward bring important across lines Thanks experienced you portfolio Anna. our people in we’ll program, generated more lead questions. to and earlier and to management cancer. open strength the team XXXX with deliver Coming look position our significant months. with to will on our progress an date, our the with we in entered coming living We catalyst ImmunoGen that another and XXXX near-term exciting stage to accelerating to the and days update productive commitment year With good on for to

Operator

of [Operator Newman Please John Instructions] We’ll now ahead. take our go first from question Canaccord.

Your line now is open.

John Newman

maybe time so Mark maturation combination PFS than I’m I were immature, in saw data seen pembrolizumab a since those October when that show. recall continued seen any us just data told that I’m data? in that any and of you’ve (inaudible) last the were signs have had back Anna, initially since and for data that you interesting year some to we data those bit wondering if presented curious Mirvetuximab especially you

Anna Berkenblit

data look in and so of the follow really year. patients following patients are terms and it is presenting forward the that to later but now I cohort, cleaning on focus and on as to on X the Pembrolizumab trial, continue FORWARD Mirvetuximab data our We phase right this we attention mature

John Newman

you Anna, reflective control what each as of And said pretty of the the arm of think us for when it question seems is you choice you a real I some world, of see you said the follow-up is that led that (inaudible); to paclitaxel the that think proportion agree I patients for you in in that previously case? be

Anna Berkenblit

Yes, that’s the case.

world use majority for three used. So a is we patients month. topotecan and approved and every common we Doxorubicin. give had ovarian receive convenient week good is Pegylated response once physicians and next given that recovered because see resistant a paclitaxel, paclitaxel they’ve The from weekly most typically neuropathy, patients cancer is to Liposomal you schedule platinum with the Primarily is from with real what a pretty buy its typically and and of data also then

Operator

We will now Michael Please take go our next Schmidt of Guggenheim. from question ahead.

Michael Schmidt

trial lot is done well one dosing of know I work I you’ve had heard then and and in from far. a so regarding prophylaxis I considered terms we’ve of ocular docs previously very Mirvetuximab another FORWARD and that the tolerated

was to potential so this in context maybe I have respect dropouts trial [sensing] what assumption incorporated And rate? with the FORWARD in wondering just you I or

Anna Berkenblit

two is for ocular the managed factors that out that arm to once adverse open to control the an for on as were the because Mirvetuximab they you Michael, potentially out took it patients and made events if to drop they assumptions out is other rate. One not dropout on when were was of There realized arm label drop the the to randomized patients study. potential we in well consideration we about because point control

making effort materials and the the we’ve study had consistent seen a And drop that with this lot across profile sure and out the our so rate we for we to ocular investigators in minimize to facing educating patients expectations. dropout put is of

Michael Schmidt

mentioned And including the FORWARD cohort? study to as just Mirvetuximab advocate, might or affect play devil’s you Avastin combination drugs study to I new carboplatin fail, and what plans should your might not to degree

Anna Berkenblit

registration on from would that a are There study so for or statistically monotherapy It really would study scenarios understand next primary that many we and Michael. to step really Mirvetuximab the it’s really combination. failed, positive would need where for one its the could why Either our data endpoint depend the significantly the is drive monotherapy development a for perspective. contemplate not

Michael Schmidt

if if Mirvetuximab last more operating or housekeeping guidance. to the you to are is just your cash activity. around that then figure are and assumptions staying commercialization then non-cash wondering guidance expenses the I And with question, that in includes was a question that regards that comp what

Mark Enyedy

both P&L comp directly includes in operating stock cash next the year. would expected for guidance that’s be expenses, there. non-cash That and Those from

Michael Schmidt

or does pending And a maybe more initial an still buildout that infrastructure or of itself? data substantial the on buildout include the commercial that is

Mark Enyedy

it So commercial organization. does the the include of buildout

guidance, staged assuming we’re that to approach and So success it’s respect with a Michael.

of the of would So building headcounts, positive but in begin readout right expense back a be of half of pre-commercial coming with the all with a the amount managing planning the goal now benefit we’re to that existing our year. with significant

Operator

Fye of will JP from We quarter now take Morgan. our next Jessica

Jessica Fye

think they of search FDA Second we if on a last interpret how would all then OS ballpark the data has the that you cleaning couple from number focus that feedback the third, that might yet, number of three the months mature targeted towards I. if is you Does imply you’re say is enrolling and on Has relevant the have your hit first A now said I that while the about can patients? occurred regulatory can OS standpoint the the confirm response i.e. enrollment events And view. enrollment to I, in filing remind of information? if for you (inaudible) here study; end of can quarter the FORWARD have think in data provided key trial, full you how that is hit? if under with you been FORWARD that much

Anna Berkenblit

but exactly recall trial. may you quote what you enrollment that last of over schedule, end the nearly patients ahead I so completed was then, months year of three of enrollment again last two schedule the quite enrolled we of the and can’t enrollment months were was So, brisk ahead brisk. percent towards

and survival regarding or points to on there. months endpoint. right in secondary show speak, targeted to FDA the to survival, my that for we question, then The the second are over expect get many significant whether so a updated the to regarding in of that not imply have are key providing survival, trial is improvement we we statements trend typically cleaning we to anything data line now, end overall finished would have overall overall so And your Regarding us and hit in all consistent overall [bid]. powered we expect as not not XXX we number with direction see were but your anticipate is data intended survival however, over day as question, to focused a study the would can been would the the third it so statistically

Operator

Jefferies. now our ahead. Biren will of go We from take Amin Please next question

Biren Amin

Just final there are to event to clarify would that cleaning in you on the response prior would the of parameters be other question would achievement over Anna. the trigger trial, What by not consider? triggered or it

Anna Berkenblit

as towards focus have no soon We clean and patients cleaning. say trial, all I the the started trial again started data again data Data to but been of enrolling on reaches was now on months the data. focused we start of throughout for as as in we can the that is course the trial there the increased end the cleaning many an there one cleaning is past trigger and

Mark Enyedy

This Mark. is

lock Just the is start patients can as patients studies, failure keep then the you first patients, have data you to those to final and your as as of your minute collect the clean down in before moves off to event. those try many mind, and you you comes screen and goal lock and get forward, down study

was activity. the higher we volume accrued, that more So the obviously the of as Anna patients saying,

So by all statement. that that’s implied was

Biren Amin

type P design FR you And just high the point in X.XXX on PFS both need of cohort less? FR or PFS see a to would the then overall cohort given hit if a the the what high of trial let’s FORWARD expressers to expressers, value I say benefit end overall and on misses, the

Anna Berkenblit

different an you you is, There designed I for exact I months but improvement don’t variance, scenarios X.X from have that because for in give looking arm X.XX delta, both study we answer, different months the experimental PFS I on claim high what you control tell looking the are to can still ITT, six a there we the overall are arm the think subset. that scenarios, subset. can can ratio will, we’re in the to in the translates which if high healthy a in in and to be and of if for success miss we so And going ITT

Biren Amin

chemotherapy expect just three allows and about on choice choice of the versus how more for of between chemo of agents, agents question in US chemo we think should trial, maybe arm the distribution the three I, do each FORWARD sites then difference Ex-US terms you of investigators of given And in one those any agent? geographic that

Anna Berkenblit

we as choice similar the regions that investigator two chemotherapies. US we distribution would practice So regarding I and chemotherapy. to be and and usage, by we used anticipate those usage we differences not in anticipated each paclitaxel of mentioned, is agent trial real in the reflect to Doxil of discussed single in chemo what the preferences do with know world for the in followed these given real about most pretty often single world choice geographic of tends regard Europe, agent topotecan, weekly and The as

Operator

question Debjit ahead. will now Chattopadhyay. next We our go Please take from

Debjit Chattopadhyay

may away but to a FORWARD Keytruda two stay going from be I’m combo. on I, part question the

the activity sense, patients, non-small the given would the you secondly make combo agents lessons sensitive (inaudible) And from you in with would think or with keytruda the carboplatin in the more the established So resistant platinum first would Keytruda setting, platinum setting. maybe pursue if not platinum that cell? resistant stick then

Anna Berkenblit

are which following cancer, still the it’s Mirvetuximab we really when in at ovarian depend pembrolizumab plus we terms patients, initially where look going it is on resistant platinum how to and maturity. data of So do explored

yet decision haven’t we there. so made And a

really could following with relevant pembrolizumab data moment, Mirvetuximab could ovarian sensitive generated at based And we’re patients carboplatin, the on cancer in in with on based platinum you that triple quite however, nice cancer, our that agree Avastin. settings. and But non-small pembrolizumab and for we cancer future. was focused the triplet therapy be agree something lung cell potentially ovarian is you with consider the I the platinum Regarding is I that had

Debjit Chattopadhyay

better obviously recently to But being used, And individual to used, a up are is of but that people catch terms that chemos, Doxil that commonly of yet seems is outcomes what more weekly for the most are in or then the previously paclitaxel approved. of was three at outcomes. spread on for chemos there versus doing weekly talks be dichotomy kind there

Anna Berkenblit

single I patients will is cancer important patient event single ovarian selection stratifying typically in and we patients agent up what think to conversation based lines around of profile, on resistant chemotherapy. including several in sequencing remind is of etcetera. I on setting chemotherapy the terms agent physician more multiple the everyone wind that our getting platinum the really patient of of adverse the trial in the are characteristics schedule therapy,

of stratification topotecan is So one versus now the one and a or the Doxil, prior paclitaxel to stratification is factor that two factor three therapies.

to when in the consideration assign balance take chemotherapy, physicians so choice arm. there’s sure factors whatever make its we’ll they the So, across stratified that investigator

Mark Enyedy

patient typically chemotherapy and the in fact a is has peripheral of patient I to be and agent the a reintroduce other got mean partner, we Taxane EU with in things XX% likely in with in US more resistant fact place part a platinum about is a patients going of that’s XX has here single about in usage the Doxorubicin is, of in based see setting platinum doublet here. Europe resistant as fall platinum sensitive percentage in in its the this higher neuropathy Taxane the platinum a market than and and usually versus so that once to get both and rather today, to like what the you

Operator

William from go will of next question Please We ahead. our Blair. take Andy Hsieh

Andy Hsieh

Curious triple avelumab on ovarian trial is to XXX, take recent Javelin arm hear Doxil. Doxil negative plus it Anna’s study versus avelumab versus this

norms view and relevance your its that control arm and potential curious to historical on for I? assumptions I underperforms think just arm Doxil actually the versus your FORWARD

Anna Berkenblit

proof for the comment But guess so the a data I arms I concept where that cancer I absolute really at early also it’s is, and would have it analysis achieved has for can’t interim I stopped and they setting think but that. progression the described in ovarian XXX inhibitors that that free value any I hazard I on platinum from for response would ovarian aware ratios, released am say they futility. Javelin topline checkpoint of what Javelin, I have believe I the seen survival trial was press not of for study resistant the don’t and rate for XXX that of point frontline also out

Operator

will Cowen. We Boris question Peaker now ahead. take next of our Please go from

Boris Peaker

a on FORWARD as just talked I’m or that the about Maybe study, XQ? you’re finish I, of details to the in we is working that XQ lot going but incremental curious, come do you think to

Mark Enyedy

haven’t We the narrowed guidance.

what today we that the in year. So and we’ve expect where half we previously to of said are is study first the the readout

Boris Peaker

of on the lot combos, study plans and the starting on a actually is data strategic lot what work the And a keeps Mirvetuximab pivotal you’ve maturing, obviously combos a the for on of any maybe of but done combos?

Anna Berkenblit

of registration We our is Mirvetuximab regimen study; in the to those Avastin have plus that the our the Mirvetuximab next of carboplatin, two studies options moment plus to thinking help and Avastin, about one we next registration data to trial. inform one moving decision triplet continue gather for at next both we’re combination regarding for is and

we to second XX XX and to with plus hope of actively we are safety efficacy forward cohort this have we enrollment enrolling that of initial December and data in we the completed initial we ahead enroll there cohort patients for published we data. the data from platinum and triplet which to and the consistency year schedule year the between call cohort we Avastin, So that then also our agnostic look have subsequently see Mirvetuximab plan which last and

so oral but are not sensitive have and the data perspective making. from PSF we while a will Now remember before in platinum these patients the triplet take cohort, decision it just for mature

Boris Peaker

XXX, there last to would and you head-to-head on my against the is development avoid what And endpoints you question I’m minor can curious that? doing have just or target deal strategy

Anna Berkenblit

development IMGN XXX nice there that may recall in is of therapy. investigators definitely you And with interest we’ve XXX for and in as demonstrated a continuing anti-leukemia activity. discussions So favorability quite combination

we dosing do recommended head-to-head first the be to really So, in us this phase XXX plans a the would to schedule figure for point, (inaudible). thing for X proceed At out not have to is combination. versus monotherapy what do

Operator

now next Jonathan will Leerink. ahead. from Chang go our We take from Please question

Jonathan Chang

FORWARD expected A I, can you for patients one now the that on FORWARD couples your would to expectations of talk reasons on the question questions, how second about high? confidence perform, alpha many you can control and about is be talk of the I arm then FR

Anna Berkenblit

had In has terms really we the and study which that I same confidence arm, it when that control is designed the arm it. our We all designed free control started we in of including benchmarking since where of the control increased the drugs arm study, on it AURELIA medium the can a we’re say progression the included survival X.X months.

read resistant ours. XXX disease then out in three like And that last year over patients to like was and platinum in with one one just study to CORAIL not priors that our assumption. the but prior Aurelia fall foundational was So the two study

out I were of two median they arm phase there So and three PFS think included was X again there, and trial the out the in it’s that drugs recent benchmark benchmark there our best the and are X.X in months. the control the most

in we’re So of arm. confident the control performance the

we’ve In patients question and XX% based of distribution the development high, typically eligible low negative be the folate trial of seen will – the patients have terms XX% how and that that of Mirvetuximab instead majority seen anticipate majority is or medium, the cancer epithelial many on the for will what in throughout high XX% we so be of alpha will high, program on be patients expression, regarding ovarian XX% your again of high medium about and we the that of thus based second ovarian far. anticipate we receptor our

Operator

Please from MacKay next Markets. Capital Instructions] now question go of [Operator ahead. We our take Kennan will RBC

Kennan MacKay

I another actually one have four you, a parter it’s for here.

the First options NCCN per are chemotherapy is confirm how usage are to or site platinum I are I, check I and usage no to restricted to along whether in defined wanted just lines. wanted anything patient, FORWARD or double just protocol or refractory actually this protocols – sought usage in then I those label on FORWARD defined the there guideline

the I Avastin, to therapy number free or if all it plus to the check to combo a therapy wanted referred prior see just see duration instance platinum would for therapies including this products? this three of definition with or of therapies, balance to double interval of single or referred whether of then line lines lastly carboplatin in FORWARD And total Third, prior plus this to or the line? of the if I number just therapies paclitaxel be considered response wanted prior arms and

Anna Berkenblit

the one, patients is of poorly on who small have matter their subset based disease. platinum primary doublet. therapy we no platinum do blow So their basically typically progress first The just initial initial a through cancer what. refractory excluded That and ovarian

However, disease. we refractory platinum secondary are allowing patients with

therapy, I So refractory may is that – that. second they by only. what platinum that after have primary they excluded of mean line again their we’ve on progressed But

second actually schedule use that are study chemotherapies labelled are they used, those not the the investigators your of we dose our Regarding and the dose. in question, that necessarily

to for dose and of be patients XX is example that and to square mg/meter due good mucositis that’s foot a labelled the syndrome. tolerate So tough Doxil, would

allowing XX we’re allowing mg/ a of showing we’re some essentially activity less the using given X similar than daily regimen and which we’re regimen is and similarly topotecan, a studies mg/meter bit dose and of tolerability. more weekly times topotecan better the commonly X.X square used approved So for meter square for X.XX

typically So the use we’re using the investigators in clinic. doses that

really Regarding your mean number say we when a third therapy. we of prior, of are referring, we question, lines

therapy. maintenance that of important. allowed regarding therapy stratification to the flow carbo, or Taxil, already factors of platinum-free We a choices not whatever Avastin one with whether size your And back balanced chemotherapy. had maybe and number plenty as of as arms then as given factors balance be well [chem] folate priors other response are or Avastin, investigator specific for we in random are for receptor of study, stratification alpha, for that factor hope the the But not interval considered with line last So is question, that out prior would factor.

Kennan MacKay

And adjuvant for quick on be one just disease? that or is then therapy, just neoadjuvant lines the follow-up metastatic include does and that may of

Anna Berkenblit

considered Neoadjuvant one of therapy. and adjuvant are line

Operator

back no at are I appears turn conference this would time like Mr. Mark to Enyedy. there It the questions. to further

Mark Enyedy

had Thank much. the Appreciate we call but first half you, on morning. patience forward you audio updated Thanks Operator. your very of move start for progress to to as the year. We the and keeping this challenges, look apologize the we the our remainder of through we

Operator

This participation. today’s for your you Thank concludes call.

now may You disconnect.

Immunogen (IMGN) 8 Feb 192018 Q4 Earnings call transcript